Lower Circulating Meteorin-like Protein in Morbid Obesity: An Exploratory Case–Control Study with Age- and Sex-Adjusted Sensitivity Analyses

Background/Objectives: Morbid obesity is characterized by chronic low-grade inflammation, insulin resistance, and adipose tissue dysfunction. Meteorin-like protein (Metrnl) is an adipomyokine implicated in energy metabolism and inflammatory regulation, yet human findings remain inconsistent. We compared serum Metrnl between morbidly obese adults and controls and explored associations with metabolic and inflammatory indices, with explicit attention to demographic confounding. Methods: In this single-center case–control study with prospective enrolment (15 October 2025–15 January 2026), 40 consecutive bariatric candidates with morbid obesity and 43 consecutively enrolled control adults (18–65 years) were evaluated. Serum Metrnl was measured by ELISA. Between-group comparisons used Mann–Whitney U tests; correlations used Spearman ranks with Benjamini–Hochberg false-discovery-rate (FDR) control. Discriminatory performance was assessed by ROC analysis. Age- and sex-based 1:1 propensity-score matching (PSM; n = 24 per group) and multivariable regression of log-transformed Metrnl on obesity status, age, and sex in the matched cohort (and, in a further analysis, in the full cohort of 83 participants) were performed as sensitivity analyses. Results: Unadjusted serum Metrnl was lower in morbid obesity than in controls (median 3.0 [0.2–30.1] vs. 5.2 [1.4–42.2] ng/mL; p = 0.032). ROC performance was modest (AUC 0.637, 95% CI 0.524–0.740; p = 0.026; cutoff ≤3 ng/mL: sensitivity 55%, specificity 76.74%). In the overall cohort, FDR-significant correlations were limited to HbA1c, WBC, neutrophil count (inverse), and MCV (positive). After PSM, the Metrnl difference was attenuated and no longer significant (4.8 [2.2–40.5] vs. 7.8 [1.4–41.8] ng/mL; p = 0.208). Multivariable models in the matched cohort similarly showed no independent association of obesity status with Metrnl after age and sex adjustment ((OLS p = 0.294; median regression p = 0.134); full cohort (n = 83): OLS p = 0.092; median regression p = 0.182). Conclusions: The principal finding is that the lower circulating Metrnl seen in morbid obesity in the unadjusted comparison did not remain statistically significant after age and sex adjustment, either in the matched cohort or in the full cohort; selected glycemic/hematologic correlations were exploratory, and post hoc analyses showed that the results were sensitive to cohort composition. Findings should be interpreted as exploratory and hypothesis-generating rather than as evidence of a clinically actionable diagnostic biomarker. Larger, demographically balanced longitudinal studies are required.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-17
DOI
https://doi.org/10.3390/biomedicines14112655
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lower Circulating Meteorin-like Protein in Morbid Obesity: An Exploratory Case–Control Study with Age- and Sex-Adjusted Sensitivity Analyses

Onur Ağ, Mehmet Buğra Bozan, Bekir Sarıcık, Cüneyt Kayaalp et al.
2 links
Biomedicines
Adipokines, Inflammation, and Metabolic Diseases
article

Lower Circulating Meteorin-like Protein in Morbid Obesity: An Exploratory Case–Control Study with Age- and Sex-Adjusted Sensitivity Analyses

Onur Ağ, Mehmet Buğra Bozan, Bekir Sarıcık, Cüneyt Kayaalp, Hakan Ayyıldız, Harika Gözükara Bağ, Mehmet Zeki Ogut, Nizamettin Kutluer, Harun Fener
article en

Abstract

Background/Objectives: Morbid obesity is characterized by chronic low-grade inflammation, insulin resistance, and adipose tissue dysfunction. Meteorin-like protein (Metrnl) is an adipomyokine implicated in energy metabolism and inflammatory regulation, yet human findings remain inconsistent. We compared serum Metrnl between morbidly obese adults and controls and explored associations with metabolic and inflammatory indices, with explicit attention to demographic confounding. Methods: In this single-center case–control study with prospective enrolment (15 October 2025–15 January 2026), 40 consecutive bariatric candidates with morbid obesity and 43 consecutively enrolled control adults (18–65 years) were evaluated. Serum Metrnl was measured by ELISA. Between-group comparisons used Mann–Whitney U tests; correlations used Spearman ranks with Benjamini–Hochberg false-discovery-rate (FDR) control. Discriminatory performance was assessed by ROC analysis. Age- and sex-based 1:1 propensity-score matching (PSM; n = 24 per group) and multivariable regression of log-transformed Metrnl on obesity status, age, and sex in the matched cohort (and, in a further analysis, in the full cohort of 83 participants) were performed as sensitivity analyses. Results: Unadjusted serum Metrnl was lower in morbid obesity than in controls (median 3.0 [0.2–30.1] vs. 5.2 [1.4–42.2] ng/mL; p = 0.032). ROC performance was modest (AUC 0.637, 95% CI 0.524–0.740; p = 0.026; cutoff ≤3 ng/mL: sensitivity 55%, specificity 76.74%). In the overall cohort, FDR-significant correlations were limited to HbA1c, WBC, neutrophil count (inverse), and MCV (positive). After PSM, the Metrnl difference was attenuated and no longer significant (4.8 [2.2–40.5] vs. 7.8 [1.4–41.8] ng/mL; p = 0.208). Multivariable models in the matched cohort similarly showed no independent association of obesity status with Metrnl after age and sex adjustment ((OLS p = 0.294; median regression p = 0.134); full cohort (n = 83): OLS p = 0.092; median regression p = 0.182). Conclusions: The principal finding is that the lower circulating Metrnl seen in morbid obesity in the unadjusted comparison did not remain statistically significant after age and sex adjustment, either in the matched cohort or in the full cohort; selected glycemic/hematologic correlations were exploratory, and post hoc analyses showed that the results were sensitive to cohort composition. Findings should be interpreted as exploratory and hypothesis-generating rather than as evidence of a clinically actionable diagnostic biomarker. Larger, demographically balanced longitudinal studies are required.

BiomedicinesVol. 14(11)
Inonu University (TR), Elazığ Eğitim ve Araştırma Hastanesi (TR), Atlas Üniversitesi (TR)
Good health and well-being
Adipokines, Inflammation, and Metabolic Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon